Cardiff Oncology Correlations
| CRDF Stock | USD 3.78 1.34 54.92% |
The current 90-days correlation between Cardiff Oncology and Reviva Pharmaceuticals Holdings is 0.2 (i.e., Modest diversification). The correlation of Cardiff Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Cardiff Oncology Correlation With Market
Good diversification
The correlation between Cardiff Oncology and DJI is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cardiff Oncology and DJI in the same portfolio, assuming nothing else is changed.
Cardiff |
Moving together with Cardiff Stock
Moving against Cardiff Stock
| 0.37 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.33 | DYAI | Dyadic International | PairCorr |
| 0.38 | AKAN | Akanda Corp | PairCorr |
| 0.41 | TELO | Telomir Pharmaceuticals, | PairCorr |
| 0.37 | ANRO | Alto Neuroscience, | PairCorr |
| 0.34 | TTOO | T2 Biosystms | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cardiff Stock performing well and Cardiff Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cardiff Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 5.93 | 1.52 | 0.18 | (0.57) | 5.32 | 15.38 | 40.06 | |||
| EFTR | 7.57 | (4.55) | 0.00 | 42.05 | 0.00 | 8.70 | 88.91 | |||
| PDSB | 3.59 | (0.42) | 0.00 | (1.73) | 0.00 | 8.37 | 31.83 | |||
| NAVB | 6.04 | (1.20) | 0.00 | (1.34) | 0.00 | 12.50 | 40.40 | |||
| RVPHW | 14.76 | 4.23 | 0.19 | (0.76) | 15.12 | 29.41 | 129.53 | |||
| EYEN | 6.62 | (1.95) | 0.00 | (0.66) | 0.00 | 11.86 | 92.81 | |||
| CGTX | 4.47 | (0.16) | 0.00 | (0.63) | 0.00 | 11.90 | 36.32 | |||
| RNAZ | 8.41 | 0.70 | 0.05 | (0.42) | 7.80 | 23.35 | 74.31 | |||
| KOD | 3.67 | 2.27 | 0.91 | 5.91 | 1.33 | 11.39 | 18.79 | |||
| SLS | 2.45 | (0.24) | 0.00 | (0.44) | 0.00 | 5.60 | 17.75 |
Cardiff Oncology Corporate Management
| James Levine | Chief Officer | Profile | |
| Mark Erlander | CEO Director | Profile | |
| Vicki Kelemen | Chief Officer | Profile | |
| Tod Smeal | Chief Officer | Profile | |
| Brigitte Lindsay | Senior Finance | Profile | |
| MD FACP | Chief Officer | Profile | |
| Charles RPh | Senior Affairs | Profile |